1 Thompson MG, Yoon SK, Naleway AL, et al. Association of mRNA vaccination with clinical
and virologic features of COVID-19 among US essential and frontline workers. JAMA 2022; …

Correspondence 766 www. thelancet. com/infection Vol 21 June 2021 for non-
bronchoalveolar lavage biomarkers, which have not been cleared or validated. Although this …

The pandemic spread of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2),
the cause of COVID-19, has placed lives and economies of many countries under …

The SARS-CoV-2 omicron (B. 1.1. 529) variant has rapidly become globally dominant,
displacing the previously dominant delta (B1. 617.2) variant. The viral spike (S) protein is the …

2 Kimura I, Kosugi Y, Wu J, et al. The SARS-CoV-2 lambda variant exhibits enhanced
infectivity and immune resistance. Cell Rep 2022; 38: 110218. 3 Bruel T, Hadjadj J, Maes P …

Vaccine effectiveness studies have conclusively demonstrated the benefit of COVID-19
vaccines in reducing individual symptomatic and severe disease, resulting in reduced …

Co-infection with multiple SARS-CoV-2 lineages can result in recombination of the viral
genomes and the emergence of novel, recombinant SARS-CoV-2 lineages. 1–4 In January …

2 Kimura I, Kosugi Y, Wu J, et al. The SARS-CoV-2 lambda variant exhibits enhanced
infectivity and immune resistance. Cell Rep 2022; 38: 110218. 3 Bruel T, Hadjadj J, Maes P …

Little is known about the duration and protective capacity of the humoral immune response
to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In studies from Iceland1 …

1 Bobrovitz N, Ware H, Ma X, et al. Protective effectiveness of previous SARS-CoV-2
infection and hybrid immunity against the omicron variant and severe disease: a systematic …